Published in Cancer Res on June 01, 2009
Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA (2010) 2.59
HuR function in disease. Front Biosci (Landmark Ed) (2012) 1.86
New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol (2012) 1.57
Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci (2013) 1.28
The RNA-binding protein HuR promotes glioma growth and treatment resistance. Mol Cancer Res (2011) 1.16
Versatility of RNA-Binding Proteins in Cancer. Comp Funct Genomics (2012) 1.08
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells. Cancer Res (2014) 1.05
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge. Cancer Lett (2012) 1.00
Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress. J Biol Chem (2011) 1.00
Downregulation of HuR as a new mechanism of doxorubicin resistance in breast cancer cells. Mol Cancer (2012) 0.98
Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol (2011) 0.96
High expression of HuR in cytoplasm, but not nuclei, is associated with malignant aggressiveness and prognosis in bladder cancer. PLoS One (2013) 0.96
HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther (2012) 0.95
HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer (2012) 0.92
Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem Biol (2015) 0.92
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs. PLoS One (2010) 0.90
HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol (2013) 0.89
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment. Cancer Discov (2012) 0.88
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer (2012) 0.86
Systemic therapies for pancreatic cancer--the role of pharmacogenetics. Curr Drug Targets (2012) 0.86
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial. Cancer Biol Ther (2014) 0.85
Network-based inference framework for identifying cancer genes from gene expression data. Biomed Res Int (2013) 0.84
RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes Cancer (2013) 0.83
Inhibition of caspases protects mice from radiation-induced oral mucositis and abolishes the cleavage of RNA-binding protein HuR. J Biol Chem (2013) 0.82
Attenuation of the ELAV1-like protein HuR sensitizes adenocarcinoma cells to the intrinsic apoptotic pathway by increasing the translation of caspase-2L. Cell Death Dis (2014) 0.81
Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers (Basel) (2010) 0.81
The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. Oncogene (2015) 0.81
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells. Oncotarget (2015) 0.81
The flip-flop HuR: part of the problem or the solution in fighting cancer? J Clin Invest (2011) 0.80
Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance. Int J Mol Sci (2013) 0.80
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci (2016) 0.79
Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod). Cancer Biol Ther (2013) 0.79
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol (2015) 0.78
GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR. Cell Death Dis (2016) 0.78
A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS One (2014) 0.78
Insights from the HuR-interacting transcriptome: ncRNAs, ubiquitin pathways, and patterns of secondary structure dependent RNA interactions. Mol Genet Genomics (2012) 0.77
MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Clin Epigenetics (2015) 0.77
HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells. Mol Cancer Res (2016) 0.77
Pancreatic biomarkers: could they be the answer? World J Gastroenterol (2014) 0.77
HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget (2016) 0.76
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy. Oncotarget (2016) 0.76
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol (2015) 0.76
Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol (2016) 0.75
Post-transcriptional regulation of cytokine and growth factor signaling in cancer. Cytokine Growth Factor Rev (2016) 0.75
Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer. Oncol Lett (2016) 0.75
Saturated Fatty Acids Induce Post-transcriptional Regulation of HAMP mRNA via AU-rich Element-binding Protein, Human Antigen R (HuR). J Biol Chem (2015) 0.75
Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A (2004) 5.15
Diverse molecular functions of Hu proteins. Cell Mol Life Sci (2008) 4.09
Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene (2003) 2.69
HuR: post-transcriptional paths to malignancy. RNA Biol (2005) 2.38
MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol (2008) 2.26
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res (2004) 1.79
Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res (2004) 1.58
Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res (2007) 1.41
Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther (2008) 1.18
Global analysis of HuR-regulated gene expression in colon cancer systems of reducing complexity. Gene Expr (2004) 1.12
Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol (2008) 1.08
Posttranscriptional regulation of IL-13 in T cells: role of the RNA-binding protein HuR. J Allergy Clin Immunol (2008) 1.08
Reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Mod Pathol (2007) 1.00
Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. Cancer Treat Rep (1983) 0.83
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science (2004) 11.39
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell (2007) 5.29
miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell (2009) 5.22
Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A (2004) 5.15
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J (2004) 4.45
HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev (2009) 4.41
RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci U S A (2003) 4.34
LincRNA-p21 suppresses target mRNA translation. Mol Cell (2012) 3.87
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Global analysis of stress-regulated mRNA turnover by using cDNA arrays. Proc Natl Acad Sci U S A (2002) 3.71
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg (2006) 3.35
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell (2010) 3.27
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
AGEMAP: a gene expression database for aging in mice. PLoS Genet (2007) 3.22
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
p16(INK4a) translation suppressed by miR-24. PLoS One (2008) 3.08
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 2.91
Identification and functional outcome of mRNAs associated with RNA-binding protein TIA-1. Mol Cell Biol (2005) 2.83
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A (2008) 2.76
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther (2006) 2.70
Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene (2003) 2.69
Eukaryotic initiation factor 2alpha-independent pathway of stress granule induction by the natural product pateamine A. J Biol Chem (2006) 2.67
Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle (2011) 2.67
miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle (2010) 2.63
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem (2008) 2.60
Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA (2010) 2.59
Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet (2013) 2.59
Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg (2005) 2.58
Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle (2012) 2.55
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle (2011) 2.39
P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2alpha signaling. J Biol Chem (2003) 2.38
HuR: post-transcriptional paths to malignancy. RNA Biol (2005) 2.38
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg (2004) 2.35
Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res (2003) 2.35
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
Antiapoptotic function of RNA-binding protein HuR effected through prothymosin alpha. EMBO J (2005) 2.33
Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle (2010) 2.32
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A (2008) 2.29
MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol (2008) 2.26
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther (2009) 2.25
Posttranscriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle (2007) 2.25
Analysis of turnover and translation regulatory RNA-binding protein expression through binding to cognate mRNAs. Mol Cell Biol (2007) 2.24
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol (2007) 2.20
Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol (2003) 2.20
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
Control of gene expression during T cell activation: alternate regulation of mRNA transcription and mRNA stability. BMC Genomics (2005) 2.18
Nuclear HuR accumulation through phosphorylation by Cdk1. Genes Dev (2008) 2.14
AMP-activated kinase regulates cytoplasmic HuR. Mol Cell Biol (2002) 2.14
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Major bile duct injuries associated with laparoscopic cholecystectomy: effect of surgical repair on quality of life. Ann Surg (2002) 2.09
GU-rich RNA: expanding CUGBP1 function, broadening mRNA turnover. Mol Cell (2008) 2.08
The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle (2010) 2.07
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery (2006) 2.07
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Translational control of cytochrome c by RNA-binding proteins TIA-1 and HuR. Mol Cell Biol (2006) 2.05
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron (2004) 1.99
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther (2010) 1.99
Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs. Sci Signal (2009) 1.97
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Increased AMP:ATP ratio and AMP-activated protein kinase activity during cellular senescence linked to reduced HuR function. J Biol Chem (2003) 1.95
Role of HuR in skeletal myogenesis through coordinate regulation of muscle differentiation genes. Mol Cell Biol (2003) 1.93